Prescrire's rating
- JUDGEMENT RESERVED When an immunosuppressant is being considered for children with atopic eczema, dupilumab shows some efficacy, as in adults and adolescents, based on its evaluation data. However, given the usually spontaneous improvement in this condition before adolescence, and the many unknowns regarding the long-term adverse effects of dupilumab in children, its harm-benefit balance remains uncertain. As of late 2021, in view of the potential risks to children treated with this drug, it should be reserved for use in the supervised setting of clinical trials.
©Prescrire 1 April 2022
Source: "Dupilumab (Dupixent°) in severe atopic eczema from 6 years of age" Prescrire International 2022; 31 (236): 92. Free.
Enjoy full access to Prescrire International, and support independent information
|